Demographic, clinical and laboratory characteristics of the cohort according to the PTPN22 genotypes
| AA (N=6) | GA (N=119) | GG (N=272) | p Value | |
|---|---|---|---|---|
| General demographics | ||||
| Age (years) | 65.39 (43.33–74.46) | 63.0 (55.1–69.6) | 63.09 (55.13–69.23) | 0.758 |
| Sex female, n (%) | 4 (66.7) | 88 (73.9) | 199 (73.2) | 0.922 |
| Smoking status, n (%) | ||||
| Never | 3 (50) | 49 (43.4) | 123 (45.6) | 0.658 |
| Ex-smoker | 1 (16.7) | 47 (41.6) | 101 (37.4) | |
| Current | 2 (33.3) | 17 (15) | 46 (17) | |
| RA characteristics | ||||
| General characteristics | ||||
| RF positive, n (%) | 4 (66.7) | 85 (73.9) | 205 (76.8) | 0.728 |
| Anti-CCP positive, n (%) | 4 (66.7) | 73 (65.2) | 180 (68.4) | 0.826 |
| Disease duration (years) | 12 (3.5–15) | 9(4–16.5) | 11 (4–19) | 0.616 |
| Disease activity | ||||
| CRP (mg/l) | 8 (5.5–16.0) | 8 (4–17.5) | 9 (5–20) | 0.692 |
| ESR | 18 (9.5–33.5) | 26 (10–42.5) | 20 (9–34) | 0.250 |
| DAS28 | 3.92±1.16 | 4.4±1.52 | 4.16±1.35 | 0.253 |
| Disease severity | ||||
| HAQ | 1.38 (0.63–2.19) | 1.5 (0.38–2.13) | 1.63 (0.63–2.13) | 0.922 |
| EAD, n (%) | 3 (50) | 76 (63.9) | 188 (69.1) | 0.394 |
| Joint replacement surgery, n (%) | 1 (16.7) | 35 (29.4) | 79 (29.0) | 0.797 |
| Medication | ||||
| Methotrexate, n (%) | 4 (66.7) | 65 (54.6) | 153 (56.3) | 0.829 |
| Other DMARD, n (%) | 2 (33.3) | 54 (45.4) | 138 (50.7) | 0.463 |
| Anti-TNF, n (%) | 0 (0) | 19 (16.0) | 27 (9.9) | 0.154 |
| Prednisolone, n (%) | 1 (16.7) | 47 (39.5) | 82 (30.1) | 0.135 |
| NSAID/COX II, n (%) | 4 (66.7) | 30 (25.2) | 71 (28.3) | 0.085 |
| Antihypertensives, n (%) | 2 (33.3) | 55 (46.2) | 112 (41.2) | 0.585 |
| Statin/fibrate, n (%) | 1 (16.7) | 30 (25.2) | 51 (18.8) | 0.338 |
| Lipid profile | ||||
| Total cholesterol (mmol/l) | 5.1±0.41 | 5.5±0.96 | 5.5±1.11 | 0.770 |
| HDL (mmol/l) | 1.4 (1.1–1.7) | 1.6 (1.3–1.8) | 1.6 (1.3–1.9) | 0.216 |
| LDL (mmol/l) | 3.31±1.09 | 3.33±1.06 | 3.22±1.18 | 0.761 |
| Triglycerides (mmol/l) | 0.95 (0.7–1.4) | 1.3 (1.0–1.6) | 1.2 (0.9–1.6) | 0.338 |
| ApoA (mmol/l) | 1.33±0.56 | 1.68±0.43 | 1.65±0.45 | 0.236 |
| ApoB (mmol/l) | 0.97±0.29 | 1.02±0.28 | 0.99±0.26 | 0.647 |
| Lipoprotein (a) (mmol/l) | 0.09 (0.03–0.35) | 0.06 (0.03–0.17) | 0.09(0.03–0.24) | 0.066 |
| Total cholesterol:HDL ratio | 4.09±1.09 | 3.65±0.98 | 3.51±0.99 | 0.264 |
| ApoB:ApoA1 ratio | 0.82±0.4 | 0.64±0.21 | 0.63±0.23 | 0.189 |
| NCEP-defined dyslipidaemia, n (%) | 3 (50) | 69 (58) | 154 (56.6) | 0.913 |
| Comorbidities | ||||
| Insulin resistance | ||||
| HOMA–IR | 1.56 (1.23–2.62) | 1.76 (1.13–3.09) | 1.89 (1.1–3.2) | 0.739 |
| Hypertension | ||||
| Hypertension, n (%) | 3 (50) | 86 (72.3) | 191 (70.2) | 0.496 |
| Obesity | ||||
| BMI | 25.68±4.17 | 27.74±4.79 | 27.8±5.15 | 0.596 |
| Renal function | ||||
| Full MDRD | 88.87±14.65 | 80.92±23.17 | 82.2±20.57 | 0.621 |
Results are expressed as percentages, median (25th to 75th percentile values) or mean±SD as appropriate.
For analysis of lipid levels and lipid ratios patients on statins and fibrates were excluded.
Anti-CCP, anticyclic citrullinated peptide; ApoA, apolipoprotein A; ApoB, apolipoprotein B; BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score; DMARD, disease-modifying antirheumatic drugs; EAD, extra-articular disease; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; HDL, high-density lipoprotein; HOMA–IR, homeostasis model of assessment of insulin resistance; LDL, low-density lipoprotein; MDRD, modification of diet in renal disease; NCEP, National Cholesterol Education Programme; NSAID/COX II, non-steroidal anti-inflammatory drugs/cyclooxygenase II inhibitors; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour necrosis factor.